RG
ITCI

Redmile Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Redmile Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-336,759
Closed -$5.13M – 59
2016
Q3 		$5.13M Sell
336,759
-634,806
-65% -$25.7M 0.41% 37
2016
Q2 		$37.7M Sell
971,565
-84,494
-8% -$3.04M 3.6% 10
2016
Q1 		$29.4M Sell
1,056,059
-167,658
-14% -$5.59M 3% 12
2015
Q4 		$65.8M Sell
1,223,717
-98,875
-7% -$4.99M 4.93% 5
2015
Q3 		$53M Buy
1,322,592
+712,421
+117% +$23.2M 4.01% 8
2015
Q2 		$19.5M Sell
610,171
-58,500
-9% -$1.48M 1.6% 25
2015
Q1 		$16M Sell
668,671
-322,139
-33% -$7.22M 1.43% 30
2014
Q4 		$17.5M Sell
990,810
-12,686
-1% -$198K 1.9% 20
2014
Q3 		$13.8M Buy
1,003,496
+24,050
+2% +$361K 1.59% 27
2014
Q2 		$16.5M Sell
979,446
-21,614
-2% -$357K 2% 25
2014
Q1 		$18.2M Buy
+1,001,060
New +$18.1M 2.17% 20

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group's ITCI Position: Q4 2016 in Review

Redmile Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 336,759 shares — an estimated $5.13M sold.

Redmile Group first reported a position in ITCI in Q1 2014 and held it in 11 quarters. The position peaked at $65.8M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • Redmile Group reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • Redmile Group sold 336,759 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $5.13M.
  • Redmile Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 11 quarters.
  • Redmile Group's Intra-Cellular Therapies Inc. position peaked at $65.8M in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on Redmile Group's 13F filing for Q4 2016, filed 14 Feb 2017.